RT Journal Article
T1 Prospects in Innate Immune Responses as Potential Control Strategies against Non-Primate Lentiviruses
A1 de Pablo-Maiso, Lorena
A1 Domenech Gómez, Ana María
A1 Echeverría, Irache
A1 Gómez-Arrebola, Carmen
A1 de Andrés, Damián
A1 Rosati, Sergio
A1 Gómez-Lucía Duato, María Esperanza
A1 Reina, Ramsés
AB Lentiviruses are infectious agents of a number of animal species, including sheep, goats, horses, monkeys, cows, and cats, in addition to humans. As in the human case, the host immune response fails to control the establishment of chronic persistent infection that finally leads to a specific disease development. Despite intensive research on the development of lentivirus vaccines, it is still not clear which immune responses can protect against infection. Viral mutations resulting in escape from T-cell or antibody-mediated responses are the basis of the immune failure to control the infection. The innate immune response provides the first line of defense against viral infections in an antigen-independent manner. Antiviral innate responses are conducted by dendritic cells, macrophages, and natural killer cells, often targeted by lentiviruses, and intrinsic antiviral mechanisms exerted by all cells. Intrinsic responses depend on the recognition of the viral pathogen-associated molecular patterns (PAMPs) by pathogen recognition receptors (PRRs), and the signaling cascades leading to an antiviral state by inducing the expression of antiviral proteins, including restriction factors. This review describes the latest advances on innate immunity related to the infection by animal lentiviruses, centered on small ruminant lentiviruses (SRLV), equine infectious anemia virus (EIAV), and feline (FIV) and bovine immunodeficiency viruses (BIV), specifically focusing on the antiviral role of the major restriction factors described thus far.
PB MDPI
SN 1999-4915
YR 2018
FD 2018-08-17
LK https://hdl.handle.net/20.500.14352/12537
UL https://hdl.handle.net/20.500.14352/12537
LA eng
NO Ministerio de Economía y Competitividad (MINECO)
DS Docta Complutense
RD 13 abr 2025